Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review-Reference-Cited by-同舟云学术

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

Published:2021-05-06 Issue:7 Volume:39 Page:789-807
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Dahham Jalal^ORCID,Rizk Rana^ORCID,Kremer Ingrid^ORCID,Evers Silvia M. A. A.^ORCID,Hiligsmann Mickaël^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01032-7.pdf

Reference69 articles.

1. The Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition (September 2020).

2. Dua T, Rompani P, World Health Organization, Multiple Sclerosis International Federation, editors. Atlas: multiple sclerosis resources in the world, 2008. Geneva, Switzerland: World Health Organization; 2008.

3. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology. 2016;46:209–21.

4. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:16.

5. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48–49:134–42.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The overall and smoking-attributable burden of multiple sclerosis among older adults aged 65–89 years from 1990 to 2019 and predictions to 2040;Frontiers in Medicine;2024-08-22

2. The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-08

3. Healthcare resource utilization and economic burden of multiple sclerosis in Chinese patients: results from a real-world survey;Scientific Reports;2024-07-02

4. Multiple sclerosis: economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region;Expert Review of Pharmacoeconomics & Outcomes Research;2024-06-07

5. Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study;Multiple Sclerosis and Related Disorders;2024-06